Assertio to Participate in the IAccess Alpha Virtual Best Ideas Conference on March 25-26, 2025
Assertio Holdings Is Maintained at Buy by HC Wainwright & Co.
Assertio Holdings Analyst Ratings
Express News | Assertio Holdings, Inc. : H.c. Wainwright Cuts Target Price to $3.5 From $4
The tariff war between the US and Europe is escalating, and Trump's 'tariff big stick' is making the pharmaceutical industry tremble.
Pharmaceutical companies are urging the Trump administration and EU officials to exclude Medical products from the escalation of the trade war.
New York Manufacturing Hits Low, Inflation Fears Rise
A. G. P. Maintains Assertio(ASRT.US) With Buy Rating, Cuts Target Price to $1.75
Assertio Holdings Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
Lake Street Maintains Assertio(ASRT.US) With Buy Rating, Maintains Target Price $3
Assertio Therapeutics' Earnings Call: Growth Amid Challenges
Assertio Therapeutics (ASRT) Gets a Buy From Lake Street
Assertio Therapeutics Reports 2024 Financial Results
Earnings Call Summary | Assertio(ASRT.US) Q4 2024 Earnings Conference
Assertio (ASRT) Reports Q4 Loss, Tops Revenue Estimates
Assertio | 10-K: FY2024 Annual Report
Assertio: Q4 Earnings Snapshot
Express News | Assertio Holdings Inc Outlook 2025 Net Product Sales $108.0 Million to $123.0 Million
Assertio Holdings Q4 2024 Adj. EPS $(0.03) Beats $(0.04) Estimate, Sales $32.182M Beat $28.674M Estimate
Assertio | 8-K: Assertio Reports Fourth Quarter and Full Year 2024 Financial Results
Express News | Assertio Holdings, Inc. Q4 Adjusted Ebitda USD -500 Thousand